Last SFr.1.93 CHF
Change Today -0.02 / -1.03%
Volume 9.3K
ADXN On Other Exchanges
Symbol
Exchange
ADXN is not on other exchanges.
As of 11:43 AM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

addex pharmaceuticals ltd (ADXN) Snapshot

Open
SFr.1.95
Previous Close
SFr.1.95
Day High
SFr.2.00
Day Low
SFr.1.93
52 Week High
04/22/13 - SFr.7.26
52 Week Low
03/3/14 - SFr.1.85
Market Cap
19.6M
Average Volume 10 Days
19.0K
EPS TTM
SFr.-3.41
Shares Outstanding
10.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADDEX PHARMACEUTICALS LTD (ADXN)

Related News

No related news articles were found.

addex pharmaceuticals ltd (ADXN) Related Businessweek News

No Related Businessweek News Found

addex pharmaceuticals ltd (ADXN) Details

Addex Therapeutics Ltd., together with its subsidiaries, engages in the discovery, development, and commercialization of small-molecule pharmaceutical products for the treatment of human health. The company’s lead products include dipraglurant ADX48621, a metabotropic glutamate receptor (mGluR) 5 negative allosteric modulator that is in Phase IIa clinical testing trial for the treatment of Parkinson’s disease levodopa-induced dyskinesia; and ADX71149, an mGluR2 positive allosteric modulator (PAM), which is under Phase IIa clinical testing trial to treat schizophrenia and under Phase II clinical testing trial to treat anxiety. It also develops various preclinical programs comprising GABA-BR PAM for pain, overactive bladder, and other disorders; mGluR4 PAM for the treatment of Parkinson’s, multiple sclerosis, and other diseases; GLP1R PAM for type 2 diabetes; and mGluR2 NAM for treating Alzheimer's disease and depression. In addition, the company has discovery programs to identify allosteric modulators, including TrkB PAM for neurodegenerative diseases; and TNFR1 NAM for inflammatory diseases. It has license and collaboration agreements with Janssen Pharmaceuticals Inc. and Merck Sharp & Dohme Research Ltd. The company was formerly known as Addex Pharmaceuticals Ltd. and changed its name to Addex Therapeutics Ltd. in March 2012. Addex Therapeutics Ltd. was founded in 2002 and is based in Geneva, Switzerland.

56.2 Employees
Last Reported Date: 02/28/13
Founded in 2002

addex pharmaceuticals ltd (ADXN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

addex pharmaceuticals ltd (ADXN) Key Developments

Addex Therapeutics Ltd. Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms

Addex Therapeutics Ltd. announced top-line data from a Phase 2a clinical study of ADX71149 in anxious depression, conducted by Janssen Research & Development, LLC, on behalf of its affiliate Janssen Pharmaceuticals Inc. Overall, ADX71149 was well-tolerated and treatment emergent adverse events reported were similar to those seen in previous clinical studies. Based on a preliminary analysis of the primary efficacy end point, the 6-Item Hamilton Anxiety Subscale, (HAM-A6), ADX71149 did not meet the criterion for efficacy signal detection versus placebo. The placebo response was considered acceptable. Despite a lack of signal on the primary outcome measure, treatment with ADX71149 showed efficacy signals on several anxiety measures (HDRS17 anxiety somatization factor, IDS-C30 anxiety subscale) and on all depression measures (HDRS17, HAM-D6 and IDS-C30). This study will be presented by Janssen at a future scientific meeting and submitted for publication in a peer-reviewed medical journal. Although efficacy signals were evident, overall the data does not support the further development of ADX71149 in anxious depression. Further exploration of ADX71149 in other indications remains of potential interest. This was a multicenter, double-blind, placebo-controlled, flexibly-dosed study of adjunctive ADX71149 in adults with Major Depressive Disorder (MDD) with significant anxiety symptoms. The primary objective was to evaluate efficacy, as assessed by change from baseline on a 6-item subscale of the Hamilton Anxiety Scale (HAM-A6), and overall safety and tolerability of treatment with adjunctive ADX71149 compared to placebo in subjects with MDD with anxiety symptoms being treated with an SSRI or SNRI. Secondary outcome measures included those assessing depressed mood (HDRS17; IDS-C30, HAM-D6), and anxiety (HAM-A-14; HDRS17 anxiety somatization factor, IDS-C30 anxiety subscale). The study consisted of 3 phases: a screening phase up to 2 weeks, an 8-week double-blind treatment phase (included two 4-week treatment periods), and a 2-week post-treatment (follow up) phase. Following an initial fixed up-titration from 25mg to 50mg b.i.d, ADX71149 was dosed flexibly in the range of 50mg to 150mg b.i.d. Of the 121 randomized subjects, 100 subjects (82.6%) completed the 8-week double blind treatment phase.

Addex Therapeutics and National Institute on Drug Abuse Enter Collaboration to Advance ADX71441 & ADX88178 in Drug Abuse and Addiction

Addex Therapeutics announced entering a collaboration with the National Institute on Drug Abuse to evaluate the pharmacology of ADX71441, a GABAB receptor positive allosteric modulator (PAM), and ADX88178, an mGlu4 PAM in preclinical models of drug abuse and addiction. The collaboration will evaluate Addex drug candidates, ADX71441 and ADX88178 in a battery of preclinical models to study their potential as treatments for nicotine and cocaine addiction. Both pre-clinical and clinical data suggest that activation of GABAB receptors offers a unique therapeutic opportunity to address the needs of drug abuse patients by reducing drug intake, by maintaining abstinence, and by reducing drug craving. Moreover treatment with a GABAB activator can alleviate many physical signs (GI/urinary disturbances) and emotional symptoms (anxiety) associated with withdrawal. Addex recently reported positive data with ADX71441 in two models of alcohol abuse in mice, the ethanol binge-like drinking, drinking-in-the-dark (DID) and a model of long-term, excessive drinking, intermittent access to alcohol.

Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression

Addex Therapeutics Ltd. announced that Janssen Research & Development, LLC, on behalf of Janssen Pharmaceuticals Inc., has completed enrollment of 120 patients in a multicenter, double-blind, Phase 2 study of ADX71149 in adults with major depressive disorder who are also suffering anxiety symptoms. The multicenter, double-blind, placebo-controlled study to evaluate the efficacy and overall safety and tolerability of ADX71149 (Clinicaltrials.gov ref. NCT01582815) is being conducted as an adjunctive treatment to an antidepressant in 120 adults with major depressive disorder with anxiety symptoms and partial response to SSRI/SNRI (HDRS (3) 18 and Anx/Som Factor (3) 7). Oral ADX71149 is being administered twice-daily at doses ranging from 25mg to 150mg. Patients continue to take the same daily dose of their antidepressant. The primary endpoint of the study is the change from baseline in the 6-item subscale of the Hamilton Anxiety Rating scale (HAM-A6) score. Secondary endpoints include change from baseline of several other clinician-administered rating scales designed to assess the severity of depression and anxiety symptoms.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADXN:SW SFr.1.93 CHF -0.02

ADXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADXN.
View Industry Companies
 

Industry Analysis

ADXN

Industry Average

Valuation ADXN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 127.2x
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 118.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADDEX PHARMACEUTICALS LTD, please visit www.addextherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.